Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 9/20 | 0.49 |
| ▸ | CA1 | P00915 | 9/20 | 0.49 |
| ▸ | CA2 | P00918 | 9/20 | 0.49 |
| ▸ | CA4 | P22748 | 9/20 | 0.49 |
| ▸ | CA7 | P43166 | 9/20 | 0.49 |
| ▸ | CA9 | Q16790 | 9/20 | 0.49 |
| ▸ | PAK4 | O96013 | 2/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.46 |
| ▸ | BTK | Q06187 | 2/20 | 0.44 |
| ▸ | BMPR2 | Q13873 | 3/20 | 0.43 |
| ▸ | PDE5A | O76074 | 2/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2018504 | 0.90 | PAK4 (0.54) | CA12CA1CA2CA4CA7 | |
| SCHEMBL27797070 | 0.83 | PAK4 (0.53) | PAK4BTKBMPR2PDE5AJAK1 | |
| SCHEMBL2021849 | 0.82 | PAK4 (0.49) | PAK4JAK1 | |
| SCHEMBL2022714 | 0.82 | PAK4 (0.57) | PAK4BTKBMPR2PDE5AJAK1 | |
| SCHEMBL2016134 | 0.82 | PAK4 (0.54) | PAK4BTKBMPR2PDE5AJAK1 | |
| SCHEMBL2016137 | 0.82 | PAK4 (0.54) | PAK4BTKBMPR2PDE5AJAK1 | |
| SCHEMBL2022344 | 0.81 | PAK4 (0.57) | PAK4BTKBMPR2PDE5AJAK1 | |
| SCHEMBL2022343 | 0.81 | PAK4 (0.57) | PAK4BTKBMPR2PDE5AJAK1 | |
| SCHEMBL2022312 | 0.79 | PAK4 (0.55) | PAK4BTKBMPR2PDE5AJAK1 | |
| SCHEMBL2021648 | 0.79 | PAK4 (0.53) | PAK4BTKBMPR2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110160185-A9 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | PALAU PHARMA, S.A. (ES) | 2011-06-30 | — | — | US | disclosed |
| US-20100113420-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | PALAU PHARMA, S.A. (ES) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160185-A9 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | JAK3, JAK2, JAK1 | CA12 4825/4885CA1 4820/4885CA2 4685/4885 |
| US-20100113420-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | JAK3, JAK2, JAK1 | CA12 4825/4885CA1 4820/4885CA2 4685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.